AbbVie and Pfizer-backed acute kidney injury therapy developer AM-Pharma has now raised $249m in all and will use the latest round for a phase 3 trial.
AM-Pharma, the Netherlands-based acute kidney injury therapy developer backed by pharmaceutical firm AbbVie, has collected €116m ($130m) from a consortium co-led by venture capital firm LSP and investment firm Andera Partners.
The round featured VC firms Forbion Capital Partners, Ysios Capital, Kurma Partners and Idinvest Partners, as well as VC fund BB Pureos Bioventures and healthcare-focused private equity firm Gilde Healthcare.
Founded in 2001, AM-Pharma is commercialising a drug candidate for acute kidney injury, a potentially lethal condition involving loss…
